Annovis Bio(US:ANVS)2025-11-12 22:49Clinical Trials - Annovis' pivotal Phase 3 Alzheimer's study has fully activated all 84 clinical sites and is actively recruiting participants across the U.S.[5] - The trial has shown robust participation with a screen failure rate within expected projections, and the first patients have completed the 6-month treatment period, marking a key milestone[5] - Recent biomarker results from the Phase 2/3 AD trial indicate significant reductions in neuroinflammation and neurodegeneration after treatment with buntanetap compared to placebo[5] Financial Performance - Annovis' cash and cash equivalents increased to $15.3 million as of September 30, 2025, up from $10.6 million as of December 31, 2024[10] - Research and development expenses for the three months ending September 30, 2025, were $6.3 million, compared to $2.7 million for the same period in 2024, reflecting a 133% increase[10] - General and administrative expenses decreased to $1.1 million for the three months ending September 30, 2025, down from $1.7 million in the same period of 2024[10] - Annovis reported a net loss of $7.3 million for the three months ending September 30, 2025, compared to a net loss of $12.6 million for the same period in 2024[10] - The basic and diluted net loss per common share for the three months ending September 30, 2025, was $0.37, an improvement from $0.97 for the same period in 2024[10] Intellectual Property - The company secured comprehensive global intellectual property protection for the new crystal form of buntanetap through 2046[6] Executive Changes - Mark Guerin was appointed as CFO, enhancing the executive team during a critical phase of the company's development[10]